Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EPCORITAMAB-BYSP: 978 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
978
Total FAERS Reports
341 (34.9%)
Deaths Reported
199
Hospitalizations
978
As Primary/Secondary Suspect
39
Life-Threatening
5
Disabilities
Prescription
Status

FDA Application: 761324 ·

First Report: 20210610 · Latest Report: 20250918

What Are the Most Common EPCORITAMAB-BYSP Side Effects?

#1 Most Reported
Cytokine release syndrome
369 reports (37.7%)
#2 Most Reported
Diffuse large b-cell lymphoma
206 reports (21.1%)
#3 Most Reported
Diffuse large b-cell lymphoma refractory
198 reports (20.2%)

All EPCORITAMAB-BYSP Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Cytokine release syndrome 369 37.7% 136 87
Diffuse large b-cell lymphoma 206 21.1% 112 25
Diffuse large b-cell lymphoma refractory 198 20.3% 101 25
Pyrexia 79 8.1% 29 26
Immune effector cell-associated neurotoxicity syndrome 77 7.9% 34 28
Covid-19 39 4.0% 18 18
Neutrophil count decreased 35 3.6% 11 12
Hypogammaglobulinaemia 32 3.3% 7 8
Platelet count decreased 32 3.3% 11 11
Cytomegalovirus infection 31 3.2% 10 12
Pneumonia 29 3.0% 16 13
Cytomegalovirus infection reactivation 26 2.7% 7 5
Death 25 2.6% 25 4
Malignant neoplasm progression 24 2.5% 10 1
Hypoalbuminaemia 20 2.0% 8 4
Malaise 20 2.0% 7 8
Blood lactate dehydrogenase increased 18 1.8% 7 1
Delirium 18 1.8% 2 1
Infection 18 1.8% 4 6
Sepsis 18 1.8% 12 10

Who Reports EPCORITAMAB-BYSP Side Effects? Age & Gender Data

Gender: 41.6% female, 58.4% male. Average age: 71.6 years. Most reports from: JP. View detailed demographics →

Is EPCORITAMAB-BYSP Getting Safer? Reports by Year

YearReportsDeathsHosp.
2021 1 1 1
2023 100 34 35
2024 500 194 112
2025 115 50 13

View full timeline →

What Is EPCORITAMAB-BYSP Used For?

IndicationReports
Diffuse large b-cell lymphoma 362
Diffuse large b-cell lymphoma refractory 353
Product used for unknown indication 64
Diffuse large b-cell lymphoma recurrent 26
Follicular lymphoma 19
B-cell lymphoma 16
B-cell lymphoma refractory 15
Follicular lymphoma refractory 12
High-grade b-cell lymphoma 10
Lymphoma 7

EPCORITAMAB-BYSP vs Alternatives: Which Is Safer?

EPCORITAMAB-BYSP vs EPERISONE EPCORITAMAB-BYSP vs EPHEDRINE EPCORITAMAB-BYSP vs EPINASTINE EPCORITAMAB-BYSP vs EPINEPHRINE EPCORITAMAB-BYSP vs EPINEPHRINE\LIDOCAINE EPCORITAMAB-BYSP vs EPIPEN EPCORITAMAB-BYSP vs EPIRUBICIN EPCORITAMAB-BYSP vs EPLERENONE EPCORITAMAB-BYSP vs EPLONTERSEN EPCORITAMAB-BYSP vs EPOETIN ALFA-EPBX

Official FDA Label for EPCORITAMAB-BYSP

Official prescribing information from the FDA-approved drug label.